Tolerability of a Proprietary Larch Arabinogalactan Extract: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Healthy Subjects


In a placebo-controlled, double-blind, randomized clinical trial, the tolerability of a proprietary larch arabinogalactan preparation (ResistAidTM) was investigated. METHODS: 199 healthy participants were randomly assigned to receive either placebo (n = 98) or an arabinogalactan preparation (n = 101) over a period of 12 weeks. As safety parameters the total number of adverse events, changes in various biochemical and laboratory parameters as well as the global evaluation of tolerability by investigator and subjects compared to placebo were evaluated. RESULTS: In total 16 adverse events were observed in 16 subjects, with no difference between the arabinogalactan and the placebo group (p = 0.935). There were no differences in the mean changes of the measured biochemical and laboratory parameters. The tolerability of the arabinogalactan extract was rated as “very good” or “good” by the investigators for 99% of the subjects and by 98% subjects in self-assessment with no statistical differences to placebo. CONCLUSION: The measured parameters as well as the evaluation of the tolerability by the investigators and the subjects demonstrate a very good tolerance profile of the proprietary arabinogalactan extract with no differences to placebo when taken for 12 weeks.

Share and Cite:

B. Grube, H. Stier, L. Riede and J. Gruenwald, "Tolerability of a Proprietary Larch Arabinogalactan Extract: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Healthy Subjects," Food and Nutrition Sciences, Vol. 3 No. 11, 2012, pp. 1533-1538. doi: 10.4236/fns.2012.311200.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Natural Standard, “Arabinogalactan,” Natural Standard Monograph, 2010, pp. 1-16.
[2] P. D’Adamo, “Larch Arabinogalactan,” Journal of Naturopathic Medicine, Vol. 6, No. 1, 1996, pp. 33-37.
[3] G. S. Kelly, “Larch Arabinogalactan: Clinical Relevance of a Novel Immune-Enhancing Polysaccharide,” Alternative Medicine Review, Vol. 4, No. 2, 1999, pp. 96-103.
[4] B. Classen, S. Thude, W. Blaschek, M. Wack and C. Bodinet, “Immunomodulatory Effects of Arabinogalactan-Proteins from Baptisia and Echinacea,” Phytomedicine, Vol. 13, No. 9-10, 2006, pp. 688-694. doi:10.1016/j.phymed.2005.10.004
[5] J. Hauer and F. A. Anderer, “Mechanism of Stimulation of Human Natural Killer Cytotoxicity by Arabinogalactan from Larix Occidentalis,” Cancer Immunol Immunother, Vol. 36, No. 4, 1993, pp. 237-244. doi:10.1007/BF01740905
[6] E. M. Choi, A. J. Kim, Y. O. Kim and J. K. Hwang, “Immunomodulating Activity of Arabinogalactan and Fucoidan in Vitro,” Journal of Medicinal Food, Vol. 8, No. 4, 2005, pp. 446-453. doi:10.1089/jmf.2005.8.446
[7] M. Nantz, A. Painter, E. Parker, C. McGill and S. Percival, “Evaluation of Arabinogalactan’s Effect on Human Immunity,” The FASEB Journal, Vol. 15, No. 4, 2001, p. 633.
[8] R. R. Robinson, J. Feirtag and J. L. Slavin, “Effects of Dietary Arabinogalactan on Gastrointestinal and Blood Parameters in Healthy Human Subjects,” Journal of the American College of Nutrition, Vol. 20, No. 4, 2001, pp. 279-285.
[9] J. K. Udani, B. B. Singh, M. L. Barrett and V. J. Singh, “Proprietary Arabinogalactan Extract Increases Antibody Response to the Pneumonia Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Pilot Study in Healthy Volunteers,” Nutrition Journal, Vol. 9, 2010, p. 32.
[10] L. S. Kim, P. M. Burkholder and R. F. Waters, “Effects of Low-Dose Larch Arabinogalactan from Larix Occidentalis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study,” Journal of Evidence-Based Complementary & Alternative Medicine, Vol. 7, No. 3, 2002, pp. 221-229.
[11] C. M. Grieshop, E. A. Flickinger and G. C. Fahey, Jr., “Oral Administration of Arabinogalactan Affects Immune Status and Fecal Microbial Populations in Dogs,” Journal of Nutrition, Vol. 132, No. 3, 2002, pp. 478-482.
[12] L. S. Kim, R. F. Waters and P. M. Burkholder, “Immunological Activity of Larch Arabinogalactan and Echinacea: A Preliminary, Randomized, Double-Blind, Placebo-Controlled Trial,” Alternative Medicine Review: A Journal of Clinical Therapeutic, Vol. 7, No. 2, 2002, pp. 138-149.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.